Deborah Ramsdell, John Dawson and Bruce Wendel join PDS Biotechnology board

B.Riley raised its price target for PDS Biotechnology (PDSB) to $4.00 from $3.00, maintaining a Buy rating. The stock has gained 97% year-to-date, trading at $1.52. The upgrade follows positive trial data for PDS0301 in liver-metastatic colorectal cancer. PDSB plans to submit a Phase 3 protocol by Q4 2024, with a trial start in Q1 2027. The company also announced leadership changes and a share structure amendment.

PDS Biotechnology updated its corporate presentation, reporting strong interim results for PDS0301 in combination with chemotherapy, including a 71.4% objective response rate and median OS exceeding 34 months in a Phase 2 mCRC trial. The company also highlighted upcoming data readouts and a planned Phase 3 protocol for PDS0301, as well as results for PDS0101 in a Phase 2 trial. PDS0101 is seeking partnerships for further development.

PDS Biotechnology (NASDAQ: PDSB) is planning a Phase III trial for PDS0301 in metastatic colorectal cancer. Early studies showed promising results, with a 70% response rate at six months. The company has discussed the trial design with the FDA and aims to start the trial in early 2027. PDS0301 is being evaluated in combination with hepatic artery infusion pump therapy, which showed durable responses and manageable side effects.

PDS Biotechnology (PDSB) shares rose 13.08% on October 13, 2026, driven by positive clinical data and a financing deal. The company reported a 36% objective response rate in a Phase 2 trial published in JAMA Oncology, outperforming historical benchmarks. PDSB also secured $11.3M in funding from Nant Capital, though at a dilutive price. The stock's recent surge reflects optimism around its immunotherapy pipeline and strategic partnerships, despite its fragile financials.

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.